# 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth

- Link: https://www.thailand-business-news.com/pr-news/3s-bio-announces-2026-interim-results-innovation-driven-win-win-collaboration-and-sustainable-growth
- Published: 2026-08-21T14:39:00+07:00
- Author: PR Newswire

SHANGHAI, Aug. 21, 2026 /PRNewswire/ — 3S Bio (01530.HK) today announced its interim
results for the first half of 2026. During the period, the Company recorded revenue
of RMB 4.53 billion, representing a year-over-year growth of 3.9%. Net profit attributable
to equity holders of the Company reached RMB 1.15 billion, and adjusted operating
net profit attributable to shareholders of the parent stood at RMB 1.44 billion,
up 26.5% year-over-year. R&D expenses amounted to RMB 680 million, an increase of
24.9% year-over-year. The Company’s financial resources totaled RMB 19.4 billion,
providing a solid foundation for R&D investments and strategic initiatives. During
the first half of the year, marketing approvals for core products were obtained 
in 23 countries globally, and overseas product sales surged by 43% year-over-year,
primarily driven by the increasing market penetration of products such as rhEPO,
Yisaipu, and rhTPO in multiple emerging economies.

Since the beginning of 2026, three Class 1 innovative drugs have been approved for
marketing, and five products have advanced to the New Drug Application stage. The
Company has successfully constructed a multi-therapeutic pipeline matrix, further
consolidating its global competitiveness and advantages in core therapeutic areas.
3SBio has made significant progress in global partnerships, innovative R&D, and 
product commercialization, marching steadily toward high-quality development.

**I. Global Multi-Center Clinical Trials of PF-08634404 (SSGJ-707) Progressing Concurrently**

PF-08634404 (SSGJ-707) is an anti-PD-1/VEGF bispecific antibody independently developed
by 3SBio, widely recognized as a highly promising next-generation immuno-oncology
therapeutic. In 2025, 3SBio granted Pfizer the global development and commercialization
rights to SSGJ-707, with a total potential deal value exceeding US$6 billion. The
Company is also entitled to receive tiered, double-digit royalties based on cumulative
global net sales. Notably, the US$1.4 billion upfront payment and US$100 million
equity investment set a new record for the upfront payment of a single out-licensing
transaction for a Chinese innovative drug. During the reporting period, the Company
recognized RMB 850 million in Business Development revenue.

In 2026, Pfizer is fully accelerating the global multi-center clinical development
of SSGJ-707. Nine global multi-center clinical trials have been initiated, covering
multiple high-incidence cancers, including squamous/non-squamous non-small cell 
lung cancer, metastatic colorectal cancer, extensive-stage small cell lung cancer,
gastroesophageal cancer, hepatocellular carcinoma, metastatic urothelial carcinoma,
and renal cell carcinoma. Among these, two trials have advanced to Phase III, three
are in Phase II, and four are in Phase I. As of August 19, 11 clinical trials for
SSGJ-707 have been registered, activating over 1,361 clinical sites and expecting
to enroll 5,016 patients across 23 countries and regions. Notably, 75 clinical sites
in China are participating in nine clinical protocols, ranking second globally, 
behind only the United States. The Phase III trials cover a target patient population
of 225,000 in the U.S., underpinning its subsequent commercial potential. Moving
forward, the indication expansions and combination therapy regimens for SSGJ-707
will be continuously explored to fully unlock its global clinical value and commercial
growth potential.

**II. Intensive Realization of Innovation Value, Building New Growth Engines**

In the first half of 2026, 3SBio saw a wave of concentrated milestones across its
innovative pipeline. Three Class 1 innovative drugs were successively approved for
marketing, and five products progressed to the NDA stage, rapidly translating innovative
momentum into performance drivers.

**Three internally developed Class 1 innovative biologics were approved for marketing:**

**Yisaituo® (amdokitug injection)** was approved in February, indicated for the 
treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates
for systemic therapy or phototherapy. With core advantages including robust and 
rapid clearance of skin lesions, low immunogenicity, favorable safety and tolerability
profile, and convenient administration, Yisaituo® is poised to reshape psoriasis
treatment expectations. The product is expected to further broaden its clinical 
applications in autoimmune diseases as new indications are continuously developed.

**NuPIAO® (loncipetin alfa injection)** was approved for marketing in March 2026
as the first long-acting recombinant EPO biweekly formulation in China, indicated
for the treatment of anemia in hemodialysis patients with chronic kidney disease.
The product features an ultra-long half-life of 120 hours and low immunogenicity.
The intravenous administration route is highly suitable for hemodialysis patients,
and the "once every two weeks" dosing regimen significantly improves patient compliance
and convenience.

**Yisaina® (anflekitug injection)** was approved in August, as the first self-developed
IgG1/κ humanized anti-IL-1β monoclonal antibody in China, indicated for the treatment
of acute gouty arthritis in adults. The product offers differentiated clinical value
with rapid pain relief, long-lasting prevention of recurrence, and a favorable safety
profile, serving as a preferred alternative to traditional corticosteroid therapy
and a novel precision anti-inflammatory option for gout.

**Five products in the NDA stage are poised for launch:** 3SBio has established 
a robust pipeline of five products currently under NDA review, covering therapeutic
areas such as atopic dermatitis, ophthalmology, breast cancer, and weight management.
Among them, **NDAs have been accepted** for **611 (anti-IL-4Rα mAb)** for moderate-
to-severe atopic dermatitis in adults, and **601A (anti-VEGF mAb)** for macular 
edema following branch retinal vein occlusion. In-licensed products, including **
Liporaxel® Paclitaxel Oral Solution** for HER2-negative breast cancer, **DB-1303(
HER2 ADC)** for HER2-positive breast cancer, and **WS2403 (GLP-1 receptor agonist)**
for chronic weight management in overweight or obese adults, have also advanced 
to the NDA stage. These products are expected to be approved sequentially, providing
substantial product reserves for the Company’s sustainable growth.

**III. Constructing a Multi-Therapeutic Pipeline Matrix to Solidify Long-Term Core
Competitive Advantages**

3SBio’s R&D pipeline continues to expand, featuring 25 key investigational drug 
candidates across core therapeutic areas including hemoncology, autoimmune diseases,
nephrology, dermatology, and weight management.

**Hemato-oncology: Strategic layout of bispecific antibodies/fusion proteins to 
establish differentiated advantages.** **TPIAO® (recombinant human thrombopoietin
injection)** has been cleared by the U.S. FDA to initiate a global multi-center 
bridging clinical trial for the treatment of thrombocytopenia associated with chronic
liver disease. **705 (anti-PD-1/HER2 bispecific antibody)** has entered Phase II
clinical trials for HER2-positive solid tumors, standing as the only drug with this
target actively advancing in clinical stages in China, demonstrating significant
differentiation. **706 (anti-PD-1/PD-L1 bispecific antibody)** has entered Phase
II trials for advanced non-small cell lung cancer and advanced gastrointestinal 
tumors. **708 (anti-PD-1/TGFβ bispecific antibody), 709 (anti-PD-1/LAG-3 bispecific
antibody), and SPGL008 (anti-B7-H3 antibody/IL-15 fusion protein)** are all in Phase
I clinical trials for solid tumors. **SSS57 (long-acting ActRIIB-Ig Trap fusion 
protein)** obtained IND clearance from the U.S. FDA for hematological disorders,
marking the first innovative biased bispecific antibody entering clinical trials
in China. The hemato-oncology pipeline is being continuously optimized, building
a robust reserve of high-quality assets for long-term growth.

**Nephrology: Focusing on core unmet needs with a first-in-China novel-target portfolio.****
SSS55 (C3b bifunctional fusion protein)** has entered Phase I trials for paroxysmal
nocturnal hemoglobinuria, complement-mediated kidney diseases, and periodontitis,
demonstrating Best-In-Class potential. **SSS68 (long-acting anti-APRIL/BAFF bispecific
antibody)** has obtained IND approvals in both China and the U.S. for IgA nephropathy,
making it the only long-acting bispecific antibody for this indication to enter 
clinical trials in China.

**Dermatology and Weight Management: Exploring new frontiers and expanding pipelines.****
WS204 (clascoterone cream)** is in Phase III clinical trials for moderate-to-severe
acne vulgaris. **SSS67 (anti-ActRIIA/ActRIIB bispecific antibody)** has entered 
Phase I trials for overweight/obesity.

**Autoimmune Diseases: Multiple candidates entering pivotal trials, leading R&D 
in China.**

**Yisaituo® (amdokitug injection):** Patient enrollment completed for the Phase 
III trial in ankylosing spondylitis; first patient enrolled in the Phase III trial
for non-radiographic axial spondyloarthritis.

**Yisaina® (anflekitug injection):** Dose-exploration Phase II study for intermittent
gouty arthritis has been initiated.

**610 (anti-IL-5 mAb):** Patient enrollment completed for the Phase III trial in
severe eosinophilic asthma in adults; Phase III enrollment for severe eosinophilic
asthma in adolescents is ongoing.

**611 (anti-IL-4Rα mAb):** NDA submitted and accepted for moderate-to-severe atopic
dermatitis in adults.

**626 (anti-BDCA2 mAb):** Phase II trials for systemic lupus erythematosus and cutaneous
lupus erythematosus are being initiated.

**627 (anti-TL1A mAb):** Phase II enrollment initiated for ulcerative colitis.

**716 (OX40L/IL-31RA bispecific antibody):** Obtained IND clearances in both China
and the U.S. for atopic dermatitis, with Phase I enrollment initiated.

In the early-stage pipeline, **717 (CD3/BCMA/CD19 humanized trispecific antibody)**
for systemic lupus erythematosus/lupus nephritis/rheumatoid arthritis, **718 (anti-
TL1A/IL-23 bispecific antibody injection)** for inflammatory bowel disease, **719(
anti-TSLP/IL-4R bispecific antibody inhaler)** for asthma/chronic obstructive pulmonary
disease, and **629 (oral IL-23R peptide)** for psoriasis/inflammatory bowel disease
have all entered the IND or pre-clinical stages, showcasing the Company’s forward-
looking, end-to-end strategic layout in the autoimmune field.

**IV. ESG Practices Receive Authoritative Recognition, Demonstrating Sustainable
Development Capabilities**

3SBio has consistently integrated Environmental, Social, and Governance principles
into its entire operational and management processes. By continuously refining governance
structures, fulfilling social responsibilities, and promoting green operations, 
the Company has achieved solid results in sustainable development, earning accolades
from multiple authoritative platforms. In July 2026, 3SBio’s Wind ESG rating was
upgraded to "AA", placing it in the top 3.2% of the biotechnology industry, which
fully validates its comprehensive strength in risk management, compliance operations,
and corporate social responsibility practices. Concurrently, the Company’s implemented
public welfare initiatives were once again recognized as an "Excellent Case of Social
Responsibility among Chinese Pharmaceutical Industrial Enterprises", reflecting 
the industry’s acknowledgment of its dedication to philanthropy and corporate social
responsibility.

**Dr. Jing LOU, Chairman and Chief Executive Officer of 3SBio, commented:**

"In early 2026, the biopharmaceutical sector was designated as a emerging strategic
pillar industry in China. Amid the industry’s ongoing shift toward high-quality 
growth, innovative R&D capabilities have emerged as the core engine driving sustained
corporate expansion. Leveraging over 30 years of industry legacy, 3SBio stays true
to its fundamental principles while actively pursuing innovation. The Company will
continuously increase its R&D investment, deepen its focus on oncology, autoimmune
diseases, and nephrology, optimize its R&D pipeline, and strengthen its talent pool.
In the first half of this year, multiple approvals of key innovative drugs significantly
expanded the Company’s long-term growth prospects. Moving forward, we will continue
to accelerate the regulatory approval process for our late-stage pipeline, bringing
more innovative drugs with substantial clinical value to serve a broader patient
population."

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth ](http://www.prnasia.com/story/archive/5031191_AE31191_0?rand=184833)
